. 2024 Mar 28;10(5):612–620. doi: 10.1001/jamaoncol.2023.7333

Table 2. Radiologic and Pathologic Patient Outcomes in Neoadjuvant Checkpoint Inhibitor Studies of High-Risk Resectable Melanoma.

Study	Patients, No.	Follow-up, median (range), mo	Planned surgical resection, No.	Radiologic response, No.				Pathologic response, No.				Discordance between radiologic and pathologic response
Study	Patients, No.	Follow-up, median (range), mo	Planned surgical resection, No.	CR	PR	SD	PD	CR	nCR	PR	>PR	Discordance between radiologic and pathologic response
Amaria et al,¹³ 2018
Nivolumab	12	15.0 (5.8-22.6)	10	0	3	5	2	3	NR	NR	NR	Yes
Ipilimumab + nivolumab	11	15.6 (5.8-24.4)	11	1	7	2	1	5	NR	NR	NR	Yes
Blank et al,¹⁰ 2018
NAT arm^a	10	21.6 (15.9- NR)	10	0	4	3	1	3	3	1	2	Yes
Adjuvant arm	10	NR
Huang et al,¹⁴ 2019
NAT trial	29	25.0	29	0	3^b	3^b	NR	5	3	15	NR	No
Rozeman et al,¹⁵ 2019
Group 1	30	24.6 (21.6-27.6)	30	2	17	9	2	14	7	3	6	Yes
Group 2	30		29	3	14	10	2	17	2	4	7	Yes
Group 3	26		24	1	8	12	5	6	6	5	8	Yes
Amaria et al,¹⁶ 2022
Single NAT arm	30	24.4 (7.1-34.6)	29	0	18	9	3	17	2	2	8	Yes
Reijers et al,¹⁷ 2022
Single NAT arm	99	28.1 (25.0-33.8)	90	14	31	38	13	48	12	11	19	Yes
Patel et al,¹⁸ 2023
NAT-adjuvant arm	144^c	14.7	127	9	58	54	23	28^d	NR	NR	NR	Yes
Adjuvant only arm	151	14.7	151	NR	NR	NR	NR	NR	NR	NR	NR	NR

Abbreviations: CR, complete response; nCR, near-complete response; NAT, neoadjuvant therapy; NR, not reported; PD, progressive disease; PR, partial response; SD, stable disease.

^{^a}

In the neoadjuvant arm, radiologic data were available from 8 patients, and pathologic data from 9 patients.

^{^b}

Pathologic response was assessed in 27 patients, and radiologic response was assessed in 6 patients.

^{^c}

Three patients either withdrew consent or defected. All statistics are done with 141 as the baseline number.

^{^d}

Among 132 patients evaluated.